Trump Media and Technology Group Corp vs Eli Lilly And Co — how do they compare? Trump Media and Technology Group Corp trades at $8.12 (market cap $2.28B), while Eli Lilly And Co trades at $1,177 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 456.1× Trump Media and Technology Group Corp's market cap, and Eli Lilly And Co pays a 0.59% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and Eli Lilly And Co for 93 Days on average.
| DJT | LLY | |
|---|---|---|
Market Cap | $2.28B | $1.04T |
Volume | 3,148,379 | 3,064,878 |
Sector | Media | Health |
52-Week High | $17.07 | $1.28K |
52-Week Low | $7.06 | $799.57 |
Typical Hold Time | 17 Days | 93 Days |
Enterprise Value | $2.35B | $1.09T |
Dividend Yield | — | 0.59% |
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.125, down 1.16% with a bearish technical signal. The company shows minimal revenue of $3.68M against massive losses of -$712M, resulting in a negative net margin of -28,860%. Cash flow trends reveal heavy investing outflows, while a proposed merger with TAE Technologies aims to pivot toward fusion energy development. The stock faces significant fundamental challenges despite oversold RSI indicators.
Outlook remains highly speculative with substantial execution risks. The merger could provide long-term upside if fusion technology commercializes, but current financials and negative profitability signal extreme caution. Investors face dilution risk and cash burn with no near-term profit visibility.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →